The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

Zydus Lifesciences has partnered with Synthon BV in a deal to develop, license, supply, and commercialize a novel oncology drug in the US. The agreement aims to target a $1.5 billion market, with ...

Zydus Lifesciences Ltd on Wednesday said it has signed an exclusive development, licensing, supply and commercialisation pact with Synthon BV of the Netherlands for a novel oncology product for an ...

New Delhi, Zydus Lifesciences on Tuesday said it has acquired UK-based LiqMeds Group for GBP 68 million (around Rs 689 crore). The Ahmedabad-based group, through its wholly-owned subsidiary Zydus ...

New Delhi, Zydus Lifesciences Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 1,086.9 crore for the first quarter ended June 30, 2023 driven by strong sales growth from ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...